These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1236 related items for PubMed ID: 24506175

  • 1. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
    Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C.
    Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
    Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, Barrio J, Bory F, Almela P, Sánchez-Pobre P, Cosme A, Ortiz V, Niño P, Khorrami S, Benito LM, Carneros JA, Lamas E, Modolell I, Franco A, Ortuño J, Rodrigo L, García-Durán F, O'Callaghan E, Ponce J, Valer MP, Calvet X, H. pylori Study Group of the Asociación Española de Gastroenterología.
    Am J Gastroenterol; 2008 Jan; 103(1):71-6. PubMed ID: 17764498
    [Abstract] [Full Text] [Related]

  • 5. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP.
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [Abstract] [Full Text] [Related]

  • 6. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS.
    World J Gastroenterol; 2015 Jan 07; 21(1):351-9. PubMed ID: 25574111
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH.
    Helicobacter; 2012 Oct 07; 17(5):374-81. PubMed ID: 22967121
    [Abstract] [Full Text] [Related]

  • 9. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS, Parlak E, Filik L, Yolcu OF, Odemiş B, Ulker A, Saşmaz N, Ozden A, Sahin B.
    J Gastroenterol Hepatol; 2005 Apr 07; 20(4):637-42. PubMed ID: 15836716
    [Abstract] [Full Text] [Related]

  • 10. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y.
    Dig Liver Dis; 2016 May 07; 48(5):506-511. PubMed ID: 26847964
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection.
    Tursi A, Picchio M, Elisei W.
    J Gastrointestin Liver Dis; 2012 Jun 07; 21(2):133-8. PubMed ID: 22720300
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
    Nishizawa T, Suzuki H, Nakagawa I, Iwasaki E, Masaoka T, Hibi T.
    J Gastroenterol Hepatol; 2008 Dec 07; 23 Suppl 2():S167-70. PubMed ID: 19120892
    [Abstract] [Full Text] [Related]

  • 18. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.
    Lee HJ, Kim JI, Cheung DY, Kim TH, Jun EJ, Oh JH, Chung WC, Kim BW, Kim SS, Park SH, Kim JK.
    J Infect Dis; 2013 Oct 01; 208(7):1123-30. PubMed ID: 23801607
    [Abstract] [Full Text] [Related]

  • 19. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.
    Goh KL, Manikam J, Qua CS.
    Aliment Pharmacol Ther; 2012 May 01; 35(9):1097-102. PubMed ID: 22404486
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibility of clinical Helicobacter pylori isolates and its eradication by standard triple therapy: a study in west central region of Colombia.
    Alvarez-Aldana A, Fernandez Uribe PA, Mejía Valencia T, Guaca-Gonzalez YM, Santacruz-Ibarra JJ, Arturo-Arias BL, Castañeda-Chavez LJ, Pacheco-López R, Londoño-Giraldo LM, Moncayo-Ortiz JI.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0040124. PubMed ID: 38916348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.